Logo for Galapagos NV

Galapagos Investor Relations Material

Latest events

Logo for Galapagos NV

Q4 2023

Galapagos
Logo for Galapagos

Q4 2023

23 Feb, 2024
Logo for Galapagos

Status Update

10 Dec, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Galapagos NV

Access all reports
Segment Data
Access more data
Net revenue by
Source
Collaboration revenues
Product net sales
Expenses by
Financials
Galapagos NV is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises four Phase 2 programs, three Phase 1 trials, five pre-clinical studies, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis, and other indications. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.